Emory University Winship Cancer Institute
Emory University Winship Cancer Institute
Atlanta, Georgia, United States15 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-10-06 | NCT06377852 | |
| Comparative Autoantibody and Immunologic Cell Marker Study | AIDS, Blood-Borne Infections, Chronic Disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cytopenia, DNA Virus Infections, Digestive System Diseases, Disease Attributes, Epstein-Barr virus infection, Flaviviridae infectious disease, Genital Diseases, Guillain-Barre syndrome, HIV infectious disease, Hemic and Lymphatic Diseases, Hemorrhage, Herpesviridae infectious disease, Immunoglobulin G4-Related Disease, Infections, Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Post-Infectious Disorders, Purpura, Thrombocytopenic, Idiopathic, RNA Virus Infections, Sepsis, Signs and Symptoms, Sjogren syndrome, Skin Manifestations, Skin and Connective Tissue Diseases, Slow Virus Diseases, Stomatognathic Diseases, Systemic Inflammatory Response Syndrome, Tumor Virus Infections, Undifferentiated Connective Tissue Diseases, Urogenital Diseases, Xerostomia, arthritic joint disease, arthropathy, autoimmune disease, autoimmune disorder of the nervous system, autoimmune lymphoproliferative syndrome, blood coagulation disease, blood platelet disease, connective tissue disorder, demyelinating disease, diffuse scleroderma, dry eye syndrome, eye disorder, graft versus host disease, hematologic disorder, hemorrhagic disease, hepatitis, hepatitis C virus infection, hereditary disease, immune system disorder, immunoproliferative disorder, inborn error of immunity, infectious disease, juvenile idiopathic arthritis, lacrimal apparatus disorder, lentivirus infection, liver disorder, lymphatic system disorder, lymphoproliferative syndrome, mouth disorder, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease, peripheral nervous system disorder, polyneuropathy, polyradiculoneuropathy, purpura, rheumatic disorder, rheumatoid arthritis, salivary gland disorder, sexually transmitted disease, skin disorder, systemic lupus erythematosus, systemic sclerosis, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy, uterine carcinosarcoma, viral hepatitis, viral infectious disease, viral sexually transmitted disease | Enrolling by invitation | Not stated | 2026-10-01 | NCT02422875 | |
| A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 1 | 2026-09-28 | NCT06095089 | |
| A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-09-25 | NCT05083169 | |
| A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, cardiovascular disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-09-25 | NCT04634552 | |
| TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-09-22 | NCT02693535 | |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, adenoid cystic carcinoma, benign urinary system neoplasm, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cervix disorder, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, esophageal cancer, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gastric cancer, gastric neoplasm, gastroesophageal junction adenocarcinoma, gonadal disorder, intestinal disorder, kidney cancer, kidney disorder, lung disorder, lung neoplasm, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, melanocytic neoplasm, melanoma, metastatic melanoma, metastatic prostate carcinoma, mouth disorder, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, primitive neuroectodermal tumor, prostate cancer, prostate disorder, rectal disorder, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, salivary gland cancer, salivary gland disorder, sarcoma, skin disorder, skin neoplasm, small cell lung carcinoma, stomach disorder, transitional cell carcinoma, urinary system disorder, urothelial carcinoma, uterine disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-14 | NCT04140526 | |
| ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 1 / Phase 2 | 2026-08-31 | NCT06460298 | |
| ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC | Metastatic Castration-resistant Prostate Cancer | Active, not recruiting | Phase 1 / Phase 2 | 2026-05-22 | NCT05682443 | |
| Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-05-06 | NCT03990896 | |
| The PREDICT Registry: | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Skin and Connective Tissue Diseases, adenocarcinoma, breast carcinoma in situ, breast disorder, breast neoplasm, carcinoma, ductal breast carcinoma in situ, epithelial neoplasm, in situ carcinoma, neoplasm, skin disorder | Recruiting | Not stated | 2026-04-17 | NCT03448926 | |
| Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, carcinoma, cervix disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, head and neck squamous cell carcinoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, squamous cell carcinoma, uterine disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-03-20 | NCT02503423 | |
| A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) | Bronchiolitis Obliterans, Digestive System Diseases, Fibrosis, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sclerosis, bronchial disorder, bronchiolitis, bronchiolitis obliterans syndrome, bronchitis, cryptogenic organizing pneumonia, graft versus host disease, immune system disorder, liver disorder, lung disorder, obstructive lung disease, respiratory system disorder, respiratory tract infectious disorder | Recruiting | Phase 2 | 2025-12-15 | NCT06619561 | |
| A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) | diffuse large B-cell lymphoma | Recruiting | Phase 1 / Phase 2 | 2025-03-04 | NCT05487170 | |
| Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, acute myeloid leukemia, bone marrow disorder, graft versus host disease, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, myelodysplastic syndrome, myeloid leukemia, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2022-07-12 | NCT01744223 |